News | Antiplatelet and Anticoagulation Therapies | May 18, 2018

Lower Oral DOAC Anticoagulant Use Associated With More Thromboembolic Events Than Warfarin

Understanding the real-world performance of systemic anticoagulation in atrial fibrillation

Lower Oral DOAC Anticoagulant Use Associated With More Thromboembolic Events Than Warfarin. #HRS 2018

May 18, 2018 — Nearly half of patients prescribed warfarin and just under one third of those using newer direct oral anticoagulants do not maintain adherence above 80 percent. This leads to increased risks for thromboembolic events. This was according to a new study presented at Heart Rhythm 2018, the Heart Rhythm Society’s 39th Annual Scientific Sessions.

Anticoagulation (AC) mitigates risk of thromboembolic events (TE) in patients with non-valvular atrial fibrillation (AF or Afib). Warfarin for decades, and recently direct oral anticoagulants (DOACs — a newer term for novel oral anticoagulants, or NOAC) have been effective. Real-world data have pointed to inconsistent adherence to anticoagulation, but it is not clear if event risk is elevated during gaps or if events occur even during periods of adherence.

The cohort included 52,365 patients prescribed warfarin and 67,686 prescribed any of the four DOACs. Lower adherence occurred in 47% of patients using warfarin and 31% on DOACs. Compared to higher-adherence warfarin, thromboembolic events were 14% less likely for higher-adherence DOAC (P<0.001), 48% more likely for lower-adherence warfarin (P<0.001) and 69% more likely for lower-adherence DOAC (P<0.001).

This observational cohort study evaluated administrative claims for patients in the IBM Watson Health Market Scan databases receiving a prescription of warfarin or a DOAC for anticoagulation for nonvalvular atrial fibrillation (NVAF) from  2015 to 2016. Exclusions were CHA2 DS2-VASc 0-1, transient AF, other requirement for AC, thrombocytopenia and anemia. The remaining patients were stratified based on index prescription (warfarin or DOAC). Outcomes, through December 2016, were hospitalization for TE (ischemic stroke or systemic embolism), hemorrhagic stroke or major bleeding. Event rates are reported for warfarin and DOACs at higher adherence (dosage covering >80% of days) and lower adherence (covering 40-80% of days). A Cox proportional-hazards model will incorporate basic characteristics, comorbidities and a time-dependent covariate for anticoagulation based on prescription dosage to associate adherence to outcomes.

Researchers said they plan to update the abstract with 2017 data and use the time-dependent Cox model to determine if event risk is higher during medication usage or gaps in adherence. Patients with lower adherence may be candidates for device therapies that obviate the need for chronic AC.

The study was presented by Dhanunjaya R. Lakkireddy, M.D., FHRS, from Kansas City Heart Rhythm Institute in Overland Park, Kansas.

 

Find links to all the Heart Rhythm 2018 Late-breaking Studies

 

#HRS2018 #HRS18

Related Content

News | Antiplatelet and Anticoagulation Therapies

November 17, 2021 — Taking daily low-dose aspirin for seven years did not affect the risk of dementia or mental decline ...

Home November 17, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

November 9, 2021 — Utilizing a magnetically-controlled capsule endoscopy system, the double-blind, randomized OPT-PEACE ...

Home November 09, 2021
Home
News | Antiplatelet and Anticoagulation Therapies
October 4, 2021 — One month of dual antiplatelet therapy (DAPT) following stent implantation in high bleeding risk ...
Home October 04, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

September 1, 2021 — The STOPDAPT-2 ACS trial does not support the use of one month of dual antiplatelet therapy (DAPT) ...

Home September 01, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

September 1, 2021 – The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart ...

Home September 01, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

June 21, 2021 — The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's dabigatran etexilate ...

Home June 21, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

May 15, 2021 — The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in ...

Home May 15, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

April 28, 2021 — An analysis of the prospective Chinese Fuwai PCI Registry, confirms long-term, dual-antiplatelet ...

Home April 28, 2021
Home
Feature | Antiplatelet and Anticoagulation Therapies | By Dave Fornell, Editor

A comprehensive review or more than 80 randomized controlled trials (RCTs) investigating how to best manage optimal ...

Home March 22, 2021
Home
Videos | Antiplatelet and Anticoagulation Therapies

The COMPARE CRUSH Trial looked at the effect of per-hospital crushed prasugrel tablets in patients with STEMI planned ...

Home October 19, 2020
Home
Subscribe Now